DeVincenzo John P, Aitken Jody, Harrison Lisa
Department of Pediatrics, University of Tennessee, LeBonheur Children's Medical Center, and the Children's Foundation Research Center, Memphis, Tennessee 38103, USA.
J Pediatr. 2003 Jul;143(1):123-6. doi: 10.1016/S0022-3476(03)00213-0.
It has not been determined whether respiratory syncytial virus (RSV) fusion protein monoclonal antibody (MAb) (palivizumab) reduces infection or simply ameliorates disease. In a prospective observational study, 27 hospitalized premature infants with RSV who were not receiving MAb were compared with 10 such patients who were receiving MAb. Mean (SEM) RSV loads in the MAb and non-MAb groups were 3.36 (0.59) versus 4.89 (0.27) logPFU/ml (P=.01). Prophylactic palivizumab reduces nasal RSV in premature hospitalized infants.
呼吸道合胞病毒（RSV）融合蛋白单克隆抗体（MAb）（帕利珠单抗）是否能减少感染或只是改善疾病状况尚未确定。在一项前瞻性观察研究中，将27名未接受MAb治疗的住院RSV感染早产儿与10名接受MAb治疗的此类患者进行了比较。MAb组和非MAb组的平均（SEM）RSV载量分别为3.36（0.59）和4.89（0.27）logPFU/ml（P = 0.01）。预防性使用帕利珠单抗可降低住院早产儿鼻腔内的RSV水平。
